[go: up one dir, main page]

UA95284C2 - Антитела к рецептору инсулинподобного фактора роста i и их применение - Google Patents

Антитела к рецептору инсулинподобного фактора роста i и их применение

Info

Publication number
UA95284C2
UA95284C2 UAA200812606A UAA200812606A UA95284C2 UA 95284 C2 UA95284 C2 UA 95284C2 UA A200812606 A UAA200812606 A UA A200812606A UA A200812606 A UAA200812606 A UA A200812606A UA 95284 C2 UA95284 C2 UA 95284C2
Authority
UA
Ukraine
Prior art keywords
receptor
growth factor
antibodies against
amount
against insulin
Prior art date
Application number
UAA200812606A
Other languages
English (en)
Ukrainian (uk)
Inventor
Зильке Хансен
Клаус-Петер Кюнкеле
Дитмар Ройш
Ральф Шумахер
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95284(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA95284C2 publication Critical patent/UA95284C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Заявлено антитело, имеющее способность к связыванию с IGF-IR, которое является человеческим антителом Igg1- или Igg 3-типа и является гликозилированным сахарной цепью на остатке Asn297, причем количество остатков фукозы в сахарной цепи составляет по меньшей мере 99 % и, кроме того, количество остатков NGNA составляет 1 % или менее и/или количество остатков N-концевой альфа-1,3- галактозы составляет 1 % или меньше.
UAA200812606A 2006-04-11 2007-04-10 Антитела к рецептору инсулинподобного фактора роста i и их применение UA95284C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11

Publications (1)

Publication Number Publication Date
UA95284C2 true UA95284C2 (ru) 2011-07-25

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200812606A UA95284C2 (ru) 2006-04-11 2007-04-10 Антитела к рецептору инсулинподобного фактора роста i и их применение

Country Status (20)

Country Link
US (1) US20080014203A1 (ru)
EP (2) EP2007810B1 (ru)
JP (1) JP4718634B2 (ru)
KR (2) KR101276513B1 (ru)
CN (1) CN101421305B (ru)
AR (1) AR060592A1 (ru)
AU (1) AU2007236199B2 (ru)
BR (1) BRPI0710185B8 (ru)
CA (2) CA2647181C (ru)
CR (1) CR10301A (ru)
EC (1) ECSP088816A (ru)
ES (1) ES2403075T3 (ru)
IL (1) IL194397A (ru)
MX (1) MX2008012950A (ru)
NO (1) NO20084082L (ru)
NZ (1) NZ571414A (ru)
RU (1) RU2541765C2 (ru)
UA (1) UA95284C2 (ru)
WO (1) WO2007115814A2 (ru)
ZA (1) ZA200808597B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009080278A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
CN102227226B (zh) 2008-12-12 2015-05-13 贝林格尔.英格海姆国际有限公司 抗igf抗体
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
JP5921433B2 (ja) 2009-07-24 2016-05-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 攪拌システム
US9056907B2 (en) 2009-10-07 2015-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (IGF) system
ES2622366T3 (es) 2009-10-26 2017-07-06 F. Hoffmann-La Roche Ag Procedimiento para la producción de una inmunoglobulina glucosilada
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
WO2012059495A1 (en) 2010-11-05 2012-05-10 F. Hoffmann-La Roche Ag Optimized method for antibody capturing by mixed mode chromatography
AU2012274127B2 (en) 2011-06-22 2017-06-22 F. Hoffmann-La Roche Ag Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014096015A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
AR120719A1 (es) * 2019-12-10 2022-03-09 Horizon Therapeutics Ireland Designated Activity Company Anticuerpos glicosilados contra el receptor del factor de crecimiento i similar a la insulina y sus usos
CR20230204A (es) 2020-10-14 2023-10-11 Viridian Therapeutics Inc Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
WO2000061739A1 (fr) * 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP2316921B1 (en) * 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
US7378503B2 (en) * 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
EP1666501A4 (en) * 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd ANTI-HM1.24 ANTIBODIES WITH MODIFIED SUGAR CHAIN
EP1693069B1 (en) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor

Also Published As

Publication number Publication date
IL194397A (en) 2014-04-30
KR20120028396A (ko) 2012-03-22
US20080014203A1 (en) 2008-01-17
KR20080113233A (ko) 2008-12-29
ES2403075T3 (es) 2013-05-13
EP2363417A1 (en) 2011-09-07
RU2008144290A (ru) 2010-05-20
AU2007236199A1 (en) 2007-10-18
BRPI0710185A2 (pt) 2011-08-09
AU2007236199B2 (en) 2013-07-25
CA2647181A1 (en) 2007-10-18
EP2007810B1 (en) 2013-02-13
KR101276513B1 (ko) 2013-06-21
JP4718634B2 (ja) 2011-07-06
IL194397A0 (en) 2011-08-01
JP2009533367A (ja) 2009-09-17
EP2007810A2 (en) 2008-12-31
ZA200808597B (en) 2009-11-25
ECSP088816A (es) 2008-11-27
WO2007115814A2 (en) 2007-10-18
NZ571414A (en) 2011-12-22
CA3081707A1 (en) 2007-10-18
WO2007115814A3 (en) 2008-01-10
MX2008012950A (es) 2008-10-15
BRPI0710185B1 (pt) 2020-01-14
CA2647181C (en) 2020-08-11
BRPI0710185A8 (pt) 2019-01-22
BRPI0710185B8 (pt) 2021-05-25
RU2541765C2 (ru) 2015-02-20
CN101421305A (zh) 2009-04-29
AR060592A1 (es) 2008-07-02
CR10301A (es) 2008-10-29
CN101421305B (zh) 2013-05-15
NO20084082L (no) 2008-11-06

Similar Documents

Publication Publication Date Title
UA95284C2 (ru) Антитела к рецептору инсулинподобного фактора роста i и их применение
TW200833712A (en) Antibodies against insulin-like growth factor I receptor and uses thereof
CA2647288C (en) A cho-dg44 derivative cell line expressing an antibody against insulin-like growth factor receptor 1
WO2004087756A3 (en) Antibodies against insulin-like growth factor i receptor and uses thereof
WO2008006554A3 (en) Glyco-engineered antibodies
UA93488C2 (ru) Композиция анти-глипикан 3-антител, которые имеют модифицированную сахарную цепь
EP2365005A3 (en) Novel anti-IGF-IR antibodies and uses thereof
MX353319B (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
MY164461A (en) Human antibodies to human delta like ligand 4
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2005003175A3 (en) Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
IL172925A (en) Antibodies that bind to the insulin-like growth factor i receptor and their use in the preparation of pharmaceutical preparations
WO2007005786A3 (en) Methods and compositions with enhanced therapeutic activity
WO2008091641A3 (en) Compositions and methods for diagnosing and treating cancer
EP2630972A3 (en) N-terminal polysialylation
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2008094942A3 (en) Humanized antibodies against cxcr3
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2007127160A3 (en) Agrm2 antigen
WO2008036337A3 (en) Predicted phosphorylation sites
TH96999A (th) แอนตี้บอดี้ที่ถูกไกลโคซิเลท
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
MX2009006696A (es) Tratamiento de diabetes con al menos un anticuerpo especifico del receptor del factor de crecimiento epidermico o uin derivado de este.
WO2008032059A3 (en) Growth factor